奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE治疗原发性肝癌的疗效观察

Effect of oxaliplation and recombinant human endostatin combined TACE via the hepatic artery infusion treat primary liver cancer

目的 观察奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE 治疗原发性肝癌的疗效及不良反应.方法 2010 年1 月-2013 年5 月共32 例原发性肝癌患者,治疗组采用TACE 术中经肝动脉灌注奥沙利铂、重组人血管内皮抑素治疗,对照组仅采用常规TACE 治疗,术后观察两组患者不良反应,并定期检测实验室指标、肝脏评价治疗效果及不良反应.结果 治疗组的客观疗效RR 有效率（75.00%） 高于对照组（31.25%）;AFP 变化好转率（81.25%） 高于对照组（25.00%）;生活质量评价改善率（87.50%） 高于对照组（37.5%）,且毒副反应的类型及例数较对照组少.结论 TACE 术中经肝动脉灌注奥沙利铂联合重组人血管内皮抑素治疗原发性肝癌安全有效.

Objective To observe the effects of oxaliplatin and recombinant human endostatin combined with transcatheter hepatic arterial peffusion （lACE） the ecacy and adverse reaction in the treatment of primary liver cancer. Methods In 2010 January to 2013 May a total of 32 cases of primary liver cancer patients, treated with TACE by intraoperative hepatic arterial infusion of oxaliplatin and recombinant human endostatin treatment, the control group only with conventional TACE .treatment, two groups were observed in patients with postoperative untoward reaction, and regular testing laboratory indices of liver and to evaluate the therapeutic effect and adverse reaction. Results The objective effect RR the effective rates of the treatment group （75%） was higher than that of the control group （31.25%）; AFP change and improvement rate （81.25%） was higher than that of the control group （25%）; assessment of quality of life improvement rate （87.50%） was higher than that of the control group （37.5%）, the number of types and cases of adverse reactions than the control group. Conclusion Endostatin treatment of TACE by intraopamtive hepatic arterial infusion of oxaliplatin combined with recombinant human primary liver cancer is safe and effective.